BMS and Ono expand deals for Orencia and Phase II anticancer antibody
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Ono Pharmaceuticals have agreed to expand their existing agreements for two products, giving BMS broader rights to an investigational anticancer antibody and granting Ono Japanese co-commercialisation rights to BMS's arthritis drug, Orencia (abatacept).
You may also be interested in...
Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony
The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.
Titans Of Pharma 2022: Johnson & Johnson Pays Highest Exec Compensation Again
Infographic: A snapshot of executive compensation at the world’s biggest pharmaceutical companies. Explore our interactive dashboard and visualizations comparing remuneration packages with other key company metrics.